<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882866</url>
  </required_header>
  <id_info>
    <org_study_id>2018clinicethicreview215</org_study_id>
    <nct_id>NCT03882866</nct_id>
  </id_info>
  <brief_title>Iodine-125 Seed Implantation Therapy for Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>3D-printed Template for Iodine-125 Seed Implantation Therapy in Patients With Locally Advanced Pancreatic Cancer: a Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hebei General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huadong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tengzhou Central People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the application of 3D-printed template for iodine-125 seed implantation
      therapy in patients with locally advanced pancreatic cancer. Half of participants will
      receive 3D-printed coplanar template, while the other half will receive 3D-printed
      non-coplanar template.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dosimetric verification was performed after implantation. Pre- and postoperative D90, V100,
      and V150 were calculated. The success rate of iodine-125 seed implantation, dosimetric
      parameters, objective response rate (ORR)，overall survival (OS)，toxicities and quality of
      life of two treatment regimens and complications were analyzed and compared between the two
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>ORR is defined as the proportion of the subjects in the analysis population who have a complete response (CR) or partial response (PR). Responses are based on assessments per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS is defined as the time from randomization to death due to any cause, or censored at date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent toxicities of two treatment regimens in patients</measure>
    <time_frame>24 months</time_frame>
    <description>The toxicity criteria of the Radiation Therapy Oncology Group (RTOG) were applied to assess the acute and late adverse effects of irradiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of two treatment regimens in patients</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life will be evaluated using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ)C30 Questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>3D-printed non-coplanar template</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3D-printed non-coplanar template is used in this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3D-printed coplanar template</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3D-printed coplanar template is used in this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3D-printed non-coplanar template</intervention_name>
    <description>3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.</description>
    <arm_group_label>3D-printed non-coplanar template</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3D-printed coplanar template</intervention_name>
    <description>3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.</description>
    <arm_group_label>3D-printed coplanar template</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-80 years

          -  Cytologically or histologically confirmed pancreatic adenocarcinoma

          -  Inoperable locally advanced pancreatic cancer based on American Joint Committee on
             Cancer (AJCC) staging system (8th ed) (without distant metastasis)

          -  Single tumor size≤ 6 cm

          -  Karnofsky performance score （KPS）≥60

          -  Estimated survival ≥3 months

          -  Without other several comorbidity

          -  Participants must have adequate organ function:

               -  WBC≥3×109/L; HGB≥90g/dL; PLT≥50×109/L

               -  Aspartate Transaminase (AST)/alanine aminotransferase ( ALT) ≤3 × institutional
                  upper limit of normal

               -  Albumin≥3g/dL

               -  Total bilirubin ≤3mg/dL

               -  PT≤3 × institutional upper limit of normal or INR≤2.3

               -  Creatinine ≤1.5 × institutional upper limit of normal

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with other malignant tumors

          -  History of other anti-cancer therapy, including surgery,radiation, ablation and so on

          -  Pregnant or lactating women

          -  Patients with Immunodeficiency disease

          -  Several heart disease, for example: New York Heart Association (NYHA) class III/IV
             congestive heart failure，active coronary heart disease and severe arrhythmia

          -  Uncontrolled hypertension

          -  Ongoing or active infection (＞grade 2 based on National Cancer Institute-Common
             Terminology Criteria for Adverse Events (NCI-CTCAE) 4.0 edition)

          -  Active tuberculosis

          -  Chronic renal insufficiency

          -  Other organ failure

          -  History of organ transplantation

          -  History of severe mental illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhongmin Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhongmin Wang, MD</last_name>
    <phone>0086-13901848333</phone>
    <email>wzm0722@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qungang Shan, MD</last_name>
    <phone>0086-15989037568</phone>
    <email>qungangshan@sjtu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weifu Lv</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yueyong Xiao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fujun Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinhe Guo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliang Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teng Zhou Central People's Hospital</name>
      <address>
        <city>Zaozhuang</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaixian Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huadong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhongmin Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Iodine-125</keyword>
  <keyword>Three-Dimensional Printing</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>template</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

